Skip to main content
. 2020 Oct 1;26(3):e435–e444. doi: 10.1002/onco.13527

Figure 4.

Figure 4

Time to development of grade ≥2 neuropathy. Cumulative incidence functions for time to development of grade ≥2 neuropathy for (A) carboplatin plus paclitaxel and (B) paclitaxel alone according to age group and for (C) carboplatin plus paclitaxel and (D) paclitaxel alone according to performance status group.

Abbreviations: AE, adverse event; PS, performance status.